Level Biotechnology

Level Biotechnology Forward P/E

The Forward P/E Ratio of Level Biotechnology (3118.TWO) as of Nov 5, 2026 is 13.38. In the previous year, Forward P/E Ratio was 16.45 — a change of -18.68% (lower).

Forward P/E

13.38

YoY

-18.68%

Last updated:

Forward P/E Ratio of Level Biotechnology is 2025 13.38 . Forward P/E Ratio of Level Biotechnology was 2024 16.45 . It decreases by -18.68% lower compared to the previous year.

The Level Biotechnology Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
27.40 TWD
Jan 1, 2019
22.49 TWD
Jan 1, 2020
18.37 TWD
Jan 1, 2021
15.64 TWD
Jan 1, 2022
18.23 TWD
Jan 1, 2023
16.95 TWD
Jan 1, 2024
16.45 TWD
Jan 1, 2025
13.38 TWD
The Level Biotechnology Forward P/E history
YEARForward P/EYoY
13.38-18.68%
16.45-2.94%
16.95-7.06%
18.23+16.61%
15.64-14.87%
18.37-18.34%
22.49-17.90%
27.40+75.55%
15.61-7.40%
16.85+23.92%
13.60-1.98%
13.87—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Level Biotechnology Stock analysis

What does Level Biotechnology do? Level Biotechnology, Inc. generates revenue through the sale of biotechnological services and products. The company offers cell culture series, immune protein series, gene nucleic acid and molecular biology series, and instrument series to customers in the domestic market. Preclinical testing services, including genetic toxicity testing, general toxicology testing, reproductive toxicology testing, pharmacokinetic testing, and biocompatibility testing, are also provided as key revenue streams. Domestic market buyers primarily include research institutions and pharmaceutical companies seeking advanced biotech solutions. The firm's product portfolio targets the biotechnology and pharmaceutical sectors, with a focus on domestic customers. Cell culture series and molecular biology series are essential for laboratory research, while immune protein series supports immunological studies. Preclinical testing services cater to pharmaceutical firms requiring regulatory compliance for drug development. All products and services are distributed exclusively within the domestic market, ensuring focused market penetration and customer relationships. Level Biotechnology's revenue model relies on consistent demand for biotech products and testing services from domestic clients. The company's domestic market distribution strategy allows for tailored service delivery and strong client retention. By specializing in cell culture, molecular biology, and preclinical testing, Level Biotechnology maintains a competitive edge in the local biotech industry. Level Biotechnology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Level Biotechnology stock

Forward P/E Ratio of Level Biotechnology is 13.38 in 2025.

Forward P/E Ratio of Level Biotechnology changed from 16.45 to 13.38, representing a -18.68% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Level Biotechnology since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Level Biotechnology with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Level Biotechnology

All Key Metrics — Level Biotechnology